Retatrutide Breaks 30%: ADA 2026 Obesity Pipeline | Denver
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | August 3, 2026
The obesity medicine pipeline just got more interesting. Three weeks ago, Eli Lilly released topline results from two additional Phase 3 trials of retatrutide — and the data reinforce why this triple agonist is the most closely watched drug in the field. Here’s what Denver and Colorado patients need to know.
Retatrutide: 30% and Counting
Let’s start with the headline. Eli Lilly’s retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon — posted primary 80-week results from TRIUMPH-1 showing 20% body weight reduction. The extension data is what made people in the room lean forward: participants who continued to 104 weeks at the highest dose exceeded 30% weight loss. No non-surgical obesity intervention has published results like this. Full peer-reviewed data published simultaneously in the New England Journal of Medicine.
On July 23, 2026, Eli Lilly released topline results from two additional Phase 3 trials:
- TRIUMPH-2 enrolled adults with obesity and type 2 diabetes. Across the 4mg, 8mg, and 12mg dose groups at 80 weeks, participants achieved 12.7% to 20.8% mean weight loss versus 4.0% with placebo. Glycemic improvements were substantial: A1C reductions up to 1.6 percentage points from a 7.7% baseline, versus 0.2 points on placebo.
- TRIUMPH-3 enrolled 1,949 adults with severe obesity (BMI ≥35) and established cardiovascular disease, with or without type 2 diabetes. At 80 weeks, participants on retatrutide achieved up to 22.6% mean weight loss. A dedicated cardiovascular outcomes trial is currently underway to determine whether retatrutide reduces MACE events in this high-risk population — a question that will be answered definitively by that trial, not by these weight-loss endpoints.
In the companion TRANSCEND-T2D trial, retatrutide delivered a 2% A1C reduction in type 2 diabetes — on par with semaglutide and tirzepatide.
Why the 4mg Dose Matters for Your Treatment Plan
Here’s the finding that doesn’t get enough attention: participants in TRIUMPH-3 who started at the 4mg dose — a lower starting dose than typical GLP-1 initiation — achieved an average of approximately 19% body weight loss with a side effect profile comparable to or better than placebo. This is clinically meaningful. It means a simpler, gentler titration schedule may get most patients to roughly 19% weight loss, with the option to escalate to higher doses for additional response. Think of it as getting most of the benefit of a Zepbound-level result with a single dose step.
Survodutide: First Dual GLP-1/Glucagon Phase 3
From Boehringer Ingelheim: survodutide hit 16.6% weight loss at 76 weeks in SYNCHRONIZE-1. It’s a dual GLP-1/glucagon agonist — the first Phase 3 readout for that mechanism in obesity. The glucagon component appears to drive additional thermogenic and hepatic fat effects. Additional results from SYNCHRONIZE-MASLD (metabolic dysfunction-associated steatoic liver disease) were published in Nature Medicine on June 7, 2026, confirming robust liver fat reduction. Phase 3 is complete.
Amylin: A New Backbone
Amylin-based therapies are establishing themselves as a legitimate therapeutic backbone. The GI tolerability profile looks meaningfully better than current GLP-1 monotherapies, with robust weight loss signals. This is an expansion of the toolkit, not a replacement.
The Field Is Shifting
Here’s what strikes me most: the conversation has moved — at least partially — away from “how much weight can we take off?” toward composite endpoints. Resolution of obstructive sleep apnea. Liver fat reduction. BMI and A1C out of range simultaneously. We’re thinking about what obesity medicine actually resolves in a person’s life.
Colorado Context
Colorado ranks among the lower-obesity states, but Denver-metro is not immune — and prevalence has been climbing. At Clinical Nutrition Center, I work every day with people who have plateaued on current GLP-1 therapies and are asking what’s next. The retatrutide and survodutide data suggest that “next” is no longer theoretical — it’s arriving. For Denver and Colorado patients, a physician who understands this pipeline and can guide you through it before FDA approval is worth its weight in results.
Frequently Asked Questions About Retatrutide for Denver Patients
What is retatrutide and how does it work?
Retatrutide is Eli Lilly’s triple agonist obesity medication, targeting three hormone receptors simultaneously: GLP-1, GIP, and glucagon. By hitting all three pathways at once, it produces greater weight loss than single or dual agonists — up to 30% in some trial participants.
How much weight can I lose on retatrutide?
Across TRIUMPH trials, participants lost 12% to 30% of body weight depending on dose and individual factors. In TRIUMPH-3 specifically, participants with severe obesity and heart disease lost up to 22.6% of body weight at 80 weeks. The 4mg starting dose produced approximately 19% average weight loss with a favorable side effect profile — a meaningful option for many patients.
When will retatrutide be available?
Eli Lilly filed for FDA approval in Q2 2026. A decision is expected sometime between late 2026 and early 2027.
What are the side effects?
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea — consistent with the GLP-1 class. Notably, in TRIUMPH-3, participants on the 4mg dose reported side effects comparable to or better than placebo, suggesting lower doses may be better tolerated.
Will my insurance or Medicare cover retatrutide?
Coverage will depend on your plan. Medicare Bridge programs and some commercial insurers are already building coverage frameworks for the next generation of obesity medications. Our team at Clinical Nutrition Center helps patients navigate insurance and cost options before and after approval.
Can I get on retatrutide before it’s approved?
As a board-certified obesity medicine practice, we are following the retatrutide development closely and preparing our systems to onboard patients the day it receives FDA approval. If you’re on a current GLP-1 and want to discuss whether retatrutide may be a better fit for you, book a consultation — we’re the Denver-area practice that stays ahead of the pipeline.
Ready to explore what’s next for your weight-loss journey? Schedule a consultation with Dr. Lazarus or call us at (303) 750-9454. Clinical Nutrition Center serves Denver, Aurora, Highlands Ranch, Parker, and the broader Colorado Front Range.